The NYU Langone Center for Psychedelic Medicine will be part of NYU Langone’s psychiatry department and conduct health-focused research on psychedelic medicine. The health system will also launch a Psychedelic Medicine Research Training Program for early career faculty members and postdoctoral fellows seeking to become independent researchers on psychedelic medicine.
Michael Bogenschutz, MD, professor of psychiatry at the NYU Grossman School of Medicine, will serve as director of the center.
The new center is funded through more than $10 million in donations, including a $5 million donation from the neuropharmaceutical company MindMed.
To learn more, click here.
More articles on patient safety and outcomes:
14 hopsitals, health systems that have launched post-COVID-19 clinics
Cincinnati first responders deliver lungs needed for transplant amid snowstorm
36% of US adults have skipped, delayed care during pandemic, report finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
